Canagliflozin and Metformin (Invokamet®, Invokamet XR®)


Indications for Prior Authorization:

  • Indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 Diabetes Mellitus when treatment with both Canagliflozin and Metformin is appropriate
  • Limitation of use: Not for the treatment of Type 1 Diabetes Mellitus or Diabetic Ketoacidosis

Patients must meet the following criteria for the indication(s) above:

  • Patient has a diagnosis of Type 2 Diabetes Mellitus, AND
  • Patient has tried and failed a preferred SGLT2 inhibitor (e.g. Invokana® or Jardiance®) and Metformin, OR
  • Chart note documentation is provided documenting a medically appropriate reason why combination therapy is necessary, AND
  • Patient does not have a contraindication to therapy: 
    • Moderate or severe renal impairment, end-stage renal disease (ESRD), or patients on dialysis
    • Acute or chronic metabolic acidosis, including Diabetic Ketoacidosis


  • Doses are individualized based on the patient's current regimen
  • Recommended starting dose:
    • Invokamet: Canagliflozin 50mg and Metformin 500mg twice daily
    • Invokamet XR: two tablets once daily
  • Maximum daily dose of Canagliflozin is 300mg
  • Maximum daily dose of Metformin is 2,000mg


  • 1 year

Last review date: June 10, 2019

WHA is closely monitoring the Coronavirus Disease 2019 (COVID-19). Learn more about COVID-19.